Spondyloarthritis & psoriatic arthritis
Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group
Authors' conclusion
Further appraisal of candidate composite instruments is ongoing.
Study context
- Population
- GRAPPA-OMERACT Psoriatic Arthritis (PsA) working group (rheumatologists, dermatologists, methodologists, patient research partners) and Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) stakeholders10 candidate composite measures
- Outcome
- Priority for evaluating candidate PsA composite outcome measures (preliminary Delphi)
Methodological detailsconsensus/Delphi exercise, preliminary Delphi exercises, GRAPPA-OMERACT working group, Updates presented at the GRAPPA 2022 annual meeting, Initial steps: define population, purpose of use, and pros and cons of the 10 candidate instruments
- consensus/Delphi exercise
- Preliminary Delphi exercises
- GRAPPA-OMERACT working group
- Updates presented at the GRAPPA 2022 annual meeting
- Initial steps: define population, purpose of use, and pros and cons of the 10 candidate instruments
Recommendations
As reported in the abstract
- High priority: Minimal disease activity (MDA)
- Moderate priority: Disease Activity in PsA (DAPSA), American College of Rheumatology (ACR) response criteria, Psoriatic Arthritis Disease Activity Score (PASDAS), Composite Psoriatic Disease Activity Index (CPDAI), 3VAS and 4VAS
- Low priority: DAS28, Psoriatic Arthritis Responder Criteria (PsARC) and RAPID3
Original publication
Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group. J Rheumatol. Published 7 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →